Chen Yeh

Beyond tumor DNA: Establishing OncoMRD BREAST as a novel cell-free mRNA biomarker of breast tumor activity for minimal residual disease monitoring

Minimal residual disease (MRD) monitoring in breast cancer has largely relied on circulating tumor DNA (ctDNA)-based technologies, which are constrained by low tumor DNA shedding and potential confounding from clonal hematopoiesis and healthy tissues. To address these limitations, the OncoMRD BREAST assay, an 11-gene c...